Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Inventiva SA

IVA ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: STRONG BUY

Last Close

$3.60

▲ +1.41%

Market Cap $829.99M · Vol 730.40K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$829.99M

Small Cap

Div Yield

N/A

EPS Growth

+60.02%

YoY

RSI (14)

51.14

Momentum

Beta

0.68

vs Market

52W High

$7.82

54.60% below

52W Low

$2.83

25.44% above

Volume

730.40K

Avg 700.43K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

97.63%

Public shares

Shariah Compliance8 STANDARDS

✗ Inventiva SA (IVA) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does IVA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+15.76%

-1.37%

-20.70%

-31.43%

YTD

-22.58%

-32.71%

-1.91%

-74.95%

Financials & Valuation

TTM · Annual

Total Revenue	$5.27M
Net Income	$-415,520,947.00
Revenue Growth (YoY)	-99.52%
Gross Margin	100.00%
Operating Margin	-2,957.28%
Net Profit Margin	-7,899.55%
ROE	N/A
ROA · ROIC	-192.01% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	171.84
P/B	N/A
P/FCF	N/A
EPS Growth	+60.02%
Outstanding Shares	237.99M

Technical Indicators

50-Day SMA	$3.93
200-Day SMA	$4.93
RSI (14)	51.14
Beta	0.68
52-Week High	$7.82
52-Week Low	$2.83

Volume Today	730.40K
Avg Daily Volume (30D)	700.43K
Relative Volume	1.04x
Volatility (10D)	92.52
Volatility (30D)	77.65
Free Float	97.63%

Analyst Consensus

STRONG BUY

Current Price $3.60

Mean Target $13.79

52W Low$2.83 52W High$7.82

Current

Target

$2.83 $7.82

Current Analyst target

+283.16% upside potential · 9 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00VM4C3W3

ISINUS46124U1079

CountryFrance

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -6.02% ARGX.BR argenx SE -0.41% ARGX argenx SE -1.61% GMAB.CO Genmab A/S +1.30% GMAB Genmab A/S +1.09%

Company Profile

Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.